Goldman Sachs raised the firm’s price target on Teva (TEVA) to $50 from $45 and keeps a Buy rating on the shares. Teva delivered encouraging results, with strong outperformance in its branded business and additional support from a deal that appears consistent with its stated strategy of pursuing clinically de-risked, mid-sized opportunities with commercial synergies, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEVA:
- Teva price target raised to $42 from $41 at Piper Sandler
- Teva price target raised to $42 from $36 at UBS
- Teva Upgraded to $45 Price Target on Strong Execution, Emalex Acquisition, and Growing Neurology Pipeline Upside
- Teva price target raised to $45 from $42 at Truist
- Unusually active option classes on open April 29th